Assembly Biosciences, Inc. Aktie News

– Die Phase-2-Studie wird die Sicherheit, Pharmakokinetik und antivirale Aktivität von ABI-6250 bei Teilnehmern mit chronischer HDV-Infektion evaluieren – – Erste Daten aus der Phase-2-Studie werden im vierten Quartal 2027 erwartet –

– Assembly Bio wird 40 % der US‑Entwicklungskosten und Gewinne für das Helicase‑Primase‑Inhibitor‑Programm für wiederkehrende Genitalherpes teilen –

– Erweiterung der klinischen Entwicklung von ABI‑6250 auf cholestatische Lebererkrankungen, einschließlich primärer biliärer Cholangitis (PBC) und primärer sklerosierender Cholangitis (PSC) –

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming investor conferences:

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of 3,924,624 shares of its common stock at an offering price per share of common stock of $26.50, wh...

SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an aggregate of 3,358,602 shares of common stock at an offering price per share of common stock of $26....

– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV –

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) entry inhibitor, will be presented in a poster presentation at the European Association for the Stud...